NCT05395741 2026-03-25
Regbone
Institute of Mother and Child, Warsaw, Poland
Phase 1/2 Active not recruiting
Clinical Trials
12 trialsNCT03793361 2026-03-18
EREMISS
Centre Oscar Lambret
Phase 2 Completed
NCT01900743 2026-03-13
REGO-SARC
Centre Oscar Lambret
Phase 2 Completed
NCT04055220 2026-02-17
REGOSTA
Centre Leon Berard
Phase NA Recruiting
NCT06820957 2026-02-17
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
Children's Oncology Group
Phase 2/3 Active not recruiting
NCT07379047 2026-01-30
GISTAR-1
Ningbo Newbay Technology Development Co., Ltd
Phase 2/3 Not yet recruiting
NCT06087263 2026-01-20
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05830084 2026-01-06
REGO-INTER-EWI
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Active not recruiting
NCT04803877 2025-10-31
SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Active not recruiting
NCT02389244 2025-09-16
REGOBONE
UNICANCER
Phase 2 Active not recruiting
NCT05366816 2025-09-09
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
University of Miami
Phase 2 Recruiting
NCT06321055 2025-05-20
An Observational Study to Learn More About Treatment With Regorafenib in People With Advanced Gastrointestinal Stromal Tumors in the United States
Bayer
Completed